Article
Polymorphisms and overexpression of immune checkpoints PD-1, PD-L1, and CTLA-4 in DLBCL: biomarker insights from a case-control study.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Aug 2026
Arslan Unal Habibe Sema, Salim Ozan, Atas Unal, Aras Sule Darbas, Ekinci Nurten Sayin, Kilinc Yahya, Ucar Fahri
Abstract excerpt
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous lymphoma with variable treatment outcomes. Immune checkpoints are key regulators of tumor-immune interactions and important targets in cancer therapy. This study investigates the roles of PD-1, PD-L1, and CTLA-4 gene polymorphisms, along with their mRNA and protein expression, in DLBCL pathogenesis. METHODS: This case-control study...
Topics
Join the communities discussing this publication.